Featured Research

from universities, journals, and other organizations

Level of gene alters risk of Alzheimer's disease, researchers find

Date:
March 17, 2010
Source:
Mayo Clinic
Summary:
Using sophisticated techniques that scan the genomes of patients, researchers have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

Using sophisticated techniques that scan the genomes of patients, researchers at the Mayo Clinic campus in Florida have found that a gene appears to either help protect against development of Alzheimer's disease, or promote the disorder depending on the level of gene in the brain.

In two research studies published almost simultaneously in the journals Neurology and PLoS ONE, the scientists found strong evidence for the role of the gene, insulin-degrading enzyme (IDE), in influencing risk of Alzheimer's disease. The Mayo researchers were one of the groups that first found an association between IDE and Alzheimer's several years ago, but these new findings now offer a novel theory about how the gene could be involved in the disease process.

"We found a new mechanism of action for this Alzheimer's disease susceptibility gene, that acts by altering gene expression levels," says neuroscientist and neurologist Nilufer Ertekin-Taner, M.D., Ph.D., the lead investigator on the Neurology study and contributor to the PLoS ONE research.

Fanggeng Zou, Ph.D., and Minerva Carrasquillo, Ph.D., are the joint first authors of the Neurology study. Drs. Carrasquillo and Zou, Olivia Belbin, Ph.D., and Ph.D. candidate Mariet Allen are the joint first authors of the PLoS ONE study. Both studies were published online in early 2010.

IDE is known to break apart amyloid beta, the protein that clumps together in the brains of Alzheimer's patients. The Mayo researchers say their findings suggest that too little expression of IDE may promote development of the disease, while increased expression appears to protect against the disorder.

"It is an issue of the level of the normal gene, not whether a gene is in a mutant form that is not acting properly," says Dr. Ertekin-Taner. "We believe this is a novel and potentially powerful approach to understanding the complex biology behind development of Alzheimer's disease."

Until these studies, scientists have searched for Alzheimer's disease genes by looking to see if patients had different variations in genes from non-patients -- variations that increased the risk for disease development. Apolipoprotein E-4 (APOE-4) -- the only major Alzheimer's disease susceptibility gene discovered to date -- also was found that way. Humans can inherit three different forms of APOE, and researchers found that people who had one or two copies of APOE-4 have a substantially increased risk of developing Alzheimer's.

The Mayo researchers took a different tack in this research. In the Neurology study, spearheaded by Dr. Zou, they measured messenger RNA (mRNA) expression levels of 12 genes in an unaffected area of the brain in 200 people with Alzheimer's disease. These 12 genes were previously identified as potential risk genes for Alzheimer's by this group and others in the literature. They then identified genetic variations within and around these 12 genes, from among the hundreds of thousands of variations measured as part of the whole genome screen for Alzheimer's disease. That work was spearheaded by Dr. Carrasquillo in the laboratory of Steven Younkin, M.D., Ph.D., George M. Eisenberg Professor of Neuroscience at the College of Medicine, Mayo Clinic.

Measuring mRNA is a way to quantify gene expression. Genes that are activated produce more mRNA in order to make protein.

The comparison of the different gene variations and gene mRNA levels led to identification of 3 SNPs -- a form of genetic variation -- that seemed to be linked to IDE expression levels. One of these SNPs was significantly associated with both increased expression levels of IDE and reduced risk of Alzheimer's, but the researchers did not know whether these SNPs were the functional IDE variations or whether they were marking a functional, nearby IDE variant.

Drs. Younkin and Carrasquillo and their colleagues worked on that piece of the puzzle -- results of which are detailed in the PLoS One study. They identified variants in IDE in areas that are identical among humans, mice and rats. They postulated that these variants should be important in altering the function of the gene (or functional variants), because the variants reside in potentially important functional areas of the gene that are conserved between different species. When they tested these IDE variants for their effects on gene expression, they found one genetic variation that had the strongest effect on brain IDE levels and also influenced Alzheimer's disease risk. Dr. Younkin's group then tested the IDE gene with this variant in laboratory cells and showed that it led to different levels of expression of the IDE gene.

The investigators determined that the IDE variant identified in the Neurology study was a proxy (or marker) for the functional IDE variant in the PLoS ONE study. Their results suggest that genetic variation in IDE can influence levels of this gene in the brain, thereby modulating development of Alzheimer's by modifying its efficiency in breaking apart amyloid beta.

Both methods of investigations -- testing genes for their effects on disease risk and gene expression levels -- should be used in the future to look for Alzheimer's disease susceptibility genes, Dr. Ertekin-Taner says.

"We show that measuring gene expression leads us to disease susceptibility genes in a way that is more powerful than just looking for genetic variations that influence disease risk," says Dr. Ertekin-Taner. "There is no way we would have found this IDE variant if we only looked for its effect on disease risk and not gene expression."

The studies were funded by The National Institutes of Health, the Mayo Alzheimer's Disease Research Center, and the Robert and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Journal References:

  1. F. Zou, M. M. Carrasquillo, V. S. Pankratz, O. Belbin, K. Morgan, M. Allen, S. L. Wilcox, L. Ma, L. P. Walker, N. Kouri, J. D. Burgess, L. H. Younkin, Samuel G. Younkin, C. S. Younkin, G. D. Bisceglio, J. E. Crook, D. W. Dickson, R. C. Petersen, N. Graff-Radford, Steven G. Younkin, and N. Ertekin-Taner. Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Neurology, 2010; 74 (6): 480 DOI: 10.1212/WNL.0b013e3181d07654
  2. Minerva M. Carrasquillo, Olivia Belbin, Fanggeng Zou, Mariet Allen, Nilufer Ertekin-Taner, Morad Ansari, Samantha L. Wilcox, Mariah R. Kashino, Li Ma, Linda H. Younkin, Samuel G. Younkin, Curtis S. Younkin, Toros A. Dincman, Melissa E. Howard, Chanley C. Howell, Chloe M. Stanton, Christopher M. Watson, Michael Crump, Veronique Vitart, Caroline Hayward, Nicholas D. Hastie, Igor Rudan, Harry Campbell, Ozren Polasek, Kristelle Brown, Peter Passmore, David Craig, Bernadette McGuinness, Stephen Todd, Patrick G. Kehoe, David M. Mann, A. David Smith, Helen Beaumont, Donald Warden, Clive Holmes, Reinhard Heun, Heike Kφlsch, Noor Kalsheker, V. Shane Pankratz, Dennis W. Dickson, Neill R. Graff-Radford, Ronald C. Petersen, Alan F. Wright, Steven G. Younkin, Kevin Morgan. Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, Aί, and Alzheimer's Disease. PLoS ONE, 2010; 5 (1): e8764 DOI: 10.1371/journal.pone.0008764

Cite This Page:

Mayo Clinic. "Level of gene alters risk of Alzheimer's disease, researchers find." ScienceDaily. ScienceDaily, 17 March 2010. <www.sciencedaily.com/releases/2010/03/100315144820.htm>.
Mayo Clinic. (2010, March 17). Level of gene alters risk of Alzheimer's disease, researchers find. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2010/03/100315144820.htm
Mayo Clinic. "Level of gene alters risk of Alzheimer's disease, researchers find." ScienceDaily. www.sciencedaily.com/releases/2010/03/100315144820.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) — Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) — A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) — Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins